L&C Bio Co. Ltd Total Assets
L&C Bio Co. Ltd total assets. Based on the latest financial reports, L&C Bio Co. Ltd (290650) holds total assets worth ₩497.94 Billion KRW (≈ $337.45 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 290650 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of L&C Bio Co. Ltd (2015–2024)
Total assets of L&C Bio Co. Ltd from 2015 to 2024. This chart illustrates how L&C Bio Co. Ltd's total assets have evolved over time, based on quarterly financial data. See L&C Bio Co. Ltd share price for real-time trading data and today's change.
L&C Bio Co. Ltd - Asset Composition Analysis
L&C Bio Co. Ltd Total Assets Breakdown (December 2024)
L&C Bio Co. Ltd total assets breakdown as of December 2024. L&C Bio Co. Ltd's total assets of ₩497.94 Billion consist of 27.4% current assets and 72.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩18.29 Billion | 3.8% |
| Accounts Receivable | ₩21.73 Billion | 4.6% |
| Inventory | ₩46.78 Billion | 9.8% |
| Property, Plant & Equipment | ₩97.02 Billion | 20.4% |
| Intangible Assets | ₩1.93 Billion | 0.4% |
| Goodwill | ₩197.31 Billion | 41.5% |
Asset Composition Trend (2015–2024)
This chart illustrates how L&C Bio Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore L&C Bio Co. Ltd (290650) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: L&C Bio Co. Ltd's current assets represent 27.4% of total assets in 2024, a decrease from 83.5% in 2015.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 6.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 41.5% of total assets.
L&C Bio Co. Ltd Competitors by Total Assets
Key competitors of L&C Bio Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
L&C Bio Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 1.11 | 12.38 |
| Quick Ratio | 0.47 | 0.57 | 10.18 |
| Cash Ratio | 0.00 | 0.23 | 0.00 |
| Working Capital | ₩-62.47 Billion | ₩10.16 Billion | ₩41.83 Billion |
L&C Bio Co. Ltd - Advanced Valuation Insights
This section examines the relationship between L&C Bio Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 81.4% |
| Total Assets | ₩475.60 Billion |
| Market Capitalization | $402.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values L&C Bio Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: L&C Bio Co. Ltd's assets grew by 81.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for L&C Bio Co. Ltd (2015–2024)
The table below shows the annual total assets of L&C Bio Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩475.60 Billion ≈ $322.31 Million |
+81.37% |
| 2023-12-31 | ₩262.23 Billion ≈ $177.71 Million |
+31.30% |
| 2022-12-31 | ₩199.73 Billion ≈ $135.35 Million |
+85.96% |
| 2021-12-31 | ₩107.40 Billion ≈ $72.78 Million |
+33.29% |
| 2020-12-31 | ₩80.58 Billion ≈ $54.60 Million |
+21.67% |
| 2019-12-31 | ₩66.23 Billion ≈ $44.88 Million |
+15.42% |
| 2018-12-31 | ₩57.38 Billion ≈ $38.88 Million |
+180.03% |
| 2017-12-31 | ₩20.49 Billion ≈ $13.89 Million |
+30.84% |
| 2016-12-31 | ₩15.66 Billion ≈ $10.61 Million |
+71.88% |
| 2015-12-31 | ₩9.11 Billion ≈ $6.17 Million |
-- |
About L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.